Detalles de la búsqueda
1.
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
Blood
; 131(16): 1805-1808, 2018 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29386196
2.
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
Blood
; 130(20): 2196-2203, 2017 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28874350
3.
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood
; 128(11): 1458-64, 2016 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27458003
4.
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
Br J Haematol
; 175(3): 440-447, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27377168
5.
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Lancet Oncol
; 16(3): 284-92, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25683846
6.
Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.
Leukemia
; 35(12): 3578-3580, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34741117
Resultados
1 -
6
de 6
1
Próxima >
>>